LAUL.NS

Lupin Limited has a debt-to-equity ratio of 0.48, indicating a relatively conservative capital structure. The company's liquidity is assessed as medium, with a current ratio of 1.33, suggesting it has sufficient short-term assets to cover its short-term liabilities. However, the company's net cash position is negative after subtracting total debt, which could pose a liquidity risk. In terms of profitability, Lupin Limited has a return on equity (ROE) of 16.77% and a return on assets (ROA) of 8.46%. These figures are strong and suggest the company is effectively utilizing its equity and assets to generate profits. The company's operating income of 12,976.6 million INR and net income of 8,887.9 million INR further support its profitability. Lupin Limited's revenue is primarily concentrated in the pharmaceuticals segment, with no significant geographic diversification disclosed. The company's revenue of 68,129.0 million INR is derived from its core pharmaceutical business, with no material exposure to other segments or regions. The company's growth trajectory is positive, with a strong operating cash flow of 16,235.0 million INR and a free cash flow of 2,136.2 million INR. These figures indicate that the company is generating sufficient cash to fund its operations and potentially invest in growth opportunities. The capital expenditure of -10,699.5 million INR suggests the company is investing in its infrastructure and capabilities. Lupin Limited faces a medium liquidity risk, as noted in the risk assessment. The company's dilution risk is assessed as low, with no significant dilution potential identified. The company's capital structure and financial position suggest it is not currently under pressure to issue additional shares to meet its financial obligations. Recent events and filings indicate that Lupin Limited is maintaining a strong financial position. The company's financial snapshot and valuation metrics suggest it is well-positioned to continue its operations and growth initiatives. Analyst estimates provide a range of price targets, with a mean of 1,022.69 INR and a median of 1,045.00 INR, indicating a generally positive outlook from the investment community.